In a phase I study, humanized anti-CD44 monoclonal antibody RG7356 was found to be safe and well tolerated though it is not suitable as a monotherapy due to its’ limited clinical activity in AML treatment (149). Here, CD44 is linked to acute myeloid leukemia.